Destrier Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Destrier Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-329,030	Closed	-$2.44M	–	38
2015 Q3	$2.44M	Hold	329,030	–	–	0.72%	23
2015 Q2	$2.35M	Hold	329,030	–	–	0.57%	23
2015 Q1	$2.83M	Hold	329,030	–	–	0.73%	19
2014 Q4	$3.28M	Sell	329,030 -604,570	-65%	-$5.16M	0.88%	24
2014 Q3	$9.24M	Buy	933,600 +300,250	+47%	+$4.45M	2.32%	20
2014 Q2	$11M	Buy	633,350 +220,624	+53%	+$3.6M	3.63%	13
2014 Q1	$7.32M	Buy	412,726 +200,997	+95%	+$3.89M	3.62%	12
2013 Q4	$3.88M	Buy	+211,729	New	+$4M	2.57%	14

Other funds holding RPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

AIA

Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return

GCM

Gruss Capital Management New York $715M AUM 9.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

ARTA

A.R.T. Advisors New York $1.79M AUM 57.47% 1-Year Est. Return

Destrier Capital Management's RPRX Position: Q4 2015 in Review

Destrier Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q4 2015, closing a stake of 329,030 shares — an estimated $2.44M sold.

Destrier Capital Management first reported a position in RPRX in Q4 2013 and held it in 8 quarters. The position peaked at $11M in Q2 2014. 56 funds tracked by Wall St. Rank hold RPRX as of Q4 2015.

Destrier Capital Management reported no remaining Repros Therapeutics Inc. position as of Q4 2015 after selling out during the quarter.
Destrier Capital Management sold 329,030 Repros Therapeutics Inc. shares in Q4 2015, an estimated $2.44M.
Destrier Capital Management first reported a position in Repros Therapeutics Inc. in Q4 2013 and held it in 8 quarters.
Destrier Capital Management's Repros Therapeutics Inc. position peaked at $11M in Q2 2014.
56 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q4 2015.

Based on Destrier Capital Management's 13F filing for Q4 2015, filed 12 Feb 2016.